← Volver a la portada
Oceanía · Mercados regionales · Stockhead

Health Check: Actinogen shares plunge on Alzheimer’s trial miss

Publicado por Stockhead · Australia hace 28 min
Health Check: Actinogen shares plunge on Alzheimer’s trial miss
Stockhead

Resumen detallado

Actinogen shares plummeted today after the company's pivotal Alzheimer's trial missed primary endpoints. But is there still hope? ... Read More The post Health Check: Actinogen…

Actinogen's keenly-awaited Alzheimer's trail data is in – and investors are unimpressed. But the company reckons they're missing something. Pic: Getty Images

In the wake of multiple advanced drug clinical trials, biotech investors had hoped that Actinogen Medical’s (ASX:ACW) much-anticipated Alzheimer’s study results would show a clear-cut success.

Dubbed Xanamia, the 247-patient, pivotal phase IIb/III study missed its primary endpoint of being statistically superior to the placebo group.

The study also missed the secondary endpoints of improved cognition and daily living activities.

Investors vented their ire by sending Actinogen shares down as much as 4.2 cents, or 88%.

But Actinogen’s drug candidate Xanamem showed a much better effect in an older cohort with a median age of 75. These patients comprised half the total study group.

This patient grouping was “predefined”, which meant the company didn’t go data mining after the fact in a Procrustean attempt to make the data suit its purposes.

Early results from an open-label extension (OLE) study also showed disease stabilisation over 24 weeks. This readout covered the first 29 of 168 OLE patients.

Actinogen said Xanamem was “numerically but not statistically” superior to placebo, for the primary endpoint of delayed disease progression.

Inicio del artículo, extracto de Stockhead. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Stockhead Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stockhead.com.au)

También te puede interesar